Analysis of quality of life and prognosis in patients with HBV-related end-stage hepatocellular carcinoma after antiviral therapy
-
摘要: 目的探讨HBV相关终末期肝细胞癌(HCC)患者在内科保肝等治疗方案的基础上联合抗HBV治疗的获益情况。方法收集2011年1月-2012年1月于北京佑安医院就诊的初次诊断乙型肝炎肝硬化基础上的晚期HCC患者105例,根据治疗方案不同分为常规治疗组(A组,n=44)和抗病毒治疗组(B组,n=61),随访96周,通过Karnofsky评分、Child-Pugh评分、MELD评分及生存率的比较,评价患者受益情况。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验,预后分析采用Kaplan-Meier生存分析。结果随访至治疗24周时,B组患者的一般情况及肝功能与A组相比改善明显,Karnofsky评分明显提高(t=4.785,P=0.031),Child-Pugh评分明显降低(t=5.015,P=0.028);至96周时,B组患者Karnofsky评分(t=8.578,P=0.016)、ChildPugh评分(t=6.774,P=0.021)、MELD评分(t=9.014,P=0.008)与同期A组患者相比明显改善;随访96周时B组患者生存率显著高于A组,差异具有统计学意义(67.2%vs...Abstract: Objective To investigate the acquired benefit of antiviral therapy in addition to routine treatment regimen including hepatoprotective internal medicine in patients with hepatitis B virus(HBV)-related end-stage hepatocellular carcinoma(HCC).Methods A total of 105 end-stage HCC patients who were admitted to our hospital from January 2011 to January 2012 with an initial diagnosis of hepatitis B cirrhosis were included in this study.According to the treatment regimen,the patients were divided into routine treatment group(group A) and antiviral therapy group(group B).Patients were followed up for 96 weeks,and the benefit of antiviral therapy was evaluated by comparison of Karnofsky score,Child-Push score,Model for End-Stage Liver Disease(MELD) score,and survival rate between two groups.Comparison of continuous data between groups was made by t test,and comparison of categorical data was made by χ2test.Prognostic analysis was made by Kaplan-Meier survival analysis.Results At week 24 of follow-up,patients in group B had markedly improved general status and liver function,significantly increased Karnofsky score(t = 4.785,P = 0.031),and significantly reduced Child-Push score(t = 5.015,P = 0.028) compared with those in group A.At week 96,the Karnofsky score,Child-Push score,and MELD score all showed significant improvements in group B compared with those in group A(t = 8.578,P = 0.016; t = 6.774,P = 0.021; t = 9.014,P =0.008).The patients in group B had a significantly higher survival rate than those in group A(67.2% vs 45.5%,P = 0.026).Conclusion Effective antiviral therapy in patients with HBV-related end-stage HCC could improve the quality of life and liver function,reduce complications,prolong the survival time,and thus bring great benefits to those patients.
-
Key words:
- hepatitis B virus /
- carcinoma,hepatocellular /
- prognosis
本文二维码
计量
- 文章访问数: 2324
- HTML全文浏览量: 6
- PDF下载量: 446
- 被引次数: 0